NGEN Company Profile and Key Details

NervGen Pharma Corp. Common stock (NASDAQ:NGEN) closed at $3.66 USD, losing -$0.12 (-3.17%) from the previous close of $3.78. The stock is currently mid-range between its 52-week high and low $1.50 and $6.30. With a market capitalization of about $296.21 million, NervGen Pharma Corp. Common stock is classified as a micro-cap and shows market-like volatility (beta ~0.99). Key stats such as the average daily volume over the past year has been around 160.69 thousand shares, in line with its 52-week average. Headquartered in West Vancouver, BC, NervGen Pharma Corp. Common stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Adam H. Rogers, the company employs approximately 7 people and listed since February 08, 2021. NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.

Short-term trend indicators are mixed aligned (SMA20 1.03%, SMA50 -12.15%, SMA200 26.11%). The stock’s 14-day RSI is 44.32 (neutral), while the ATR of 0.29 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -33.65% below its high and over 178.67% above its low. Average 10-day trading volume of 210.96 thousand shares is slightly above the 3-month average of 156.96 thousand, indicating heightened recent market interest.

NervGen Pharma Corp. Common stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.31. This means the shares are trading above this model’s fair value.

NervGen Pharma Corp. Common stock generated EPS of -$0.26 over the past year. Five-year average earnings growth is 1.73%. Wall Street analysts project EPS growth of 1.68% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $18.00. The high target offers 391.8% upside. The low target suggests 391.8% downside. The mean target is $18.00. This offers 391.8% upside. NervGen Pharma Corp. Common stock earnings surprise history is a mixed track record. The quarter that ended March 31, 2026, missed forecasts by 125.77%.

Our AI price prediction model suggests that NervGen Pharma Corp. Common stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.56%, with price expected at $3.42 by May 18, 2026, within a range of $3.24 to $3.60 3-Month Outlook: Projected fall of -22.95%, reaching $2.82 by July 31, 2026, with a range of $2.79 to $2.85. 1-Year Outlook: Projected loss of -50.0%, with price at $1.83 by May 04, 2027, within a range of $1.79 to $1.87.

currently trading near 52-week highs band. Valuation shows NervGen Pharma Corp. Common stock trading at a premium to the broader market with a P/E of -6.02. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $18.00, suggesting 391.8% upside. Our AI forecast model points to short-term weakness (-6.56% over two weeks), a medium-term fall (-22.95% over three months), and a longer-term loss (-50.0% over one year), with expected trading ranges indicating moderate volatility.

NervGen Pharma Corp. Common stock trades at a P/E ratio of -6.02, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 76.35 reflecting a rich premium to book value. The P/FCF stands at -15.23, also above market averages. Compared to sector medians, NervGen Pharma Corp. Common stock P/S is trading at a discount to the sector, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.